J Capital
J Capital

J Capital

Coverage: Global
J Capital publishes activist research. Their work is based on primary research, fundamental analysis, and forensic accounting. Through this process J Capital seeks to identify companies trading at a significant variance to their intrinsic value.
Location: New York

Analysts

Latest articles from J Capital

CDXC: Stale News

A closer look at CDXC’s “positive” Phase 3 trial news yesterday reveals some troubling facts.   The study, conducted in Turkey, was very narrow, focused on young people without co-morbidities, whose likelihood of rapid recovery from Covid19 is hi...
J Capital Anne
Anne Stevenson-Yang @ J Capital 29 June 2021

CDXC: Unhealthy

After months of examining ChromaDex (CDXC), we have come to the conclusion that the company is pure hype, dished up by an Oceans 11 of stock promoters. CDXC promotes its single product, a health supplement, with iterative press releases that boost s....
J Capital Anne
Anne Stevenson-Yang @ J Capital 24 June 2021

BTCM: Back in the Crypto-Fraud Space

BTCM has been losing money since 2015, a year after its IPO. We think that’s intentional. We’ll show that the crypto mining plan is end-to-end hype. We found that BTCM overstated by 650% the revenue of the offshore lottery business it bought then...
J Capital Anne
Anne Stevenson-Yang @ J Capital 27 May 2021

Nearmap Gets Sued

After denying there was any problem, Nearmap (NEA ASX) has now been locked out of 65% of its U.S. sales by an ironclad patent challenge. After paying heavy damages, Nearmap is unlikely ever to be profitable in the U.S. It will mean losing 39% of tot....
J Capital Tim
Tim Murray @ J Capital 6 May 2021

Nearmap: Supersize Me

J Capital Tim
Tim Murray @ J Capital 15 February 2021

Nearmap: Failed US Strategy

J Capital Tim
Tim Murray @ J Capital 10 February 2021